RTX001 Autologous Engineered Macrophages for Liver Cirrhosis

Clinical trial NCT06823713 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06823713
Sponsor: Resolution Therapeutics Limited
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

End-stage Liver Disease (ESLD)Cirrhosis, Liver Cirrhosis, Decompensated Liver Diseases Fibrosis and Cirrhosis of Liver Decompensated Liver Cirrhosis Decompensated Cirrhosis Steatotic Liver Disease

Start date: 2024-10-15
Primary completion: 2028-08-29
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.